New option offers hope for people with severe fatty liver disease
A new treatment option for people with severe fatty liver disease has been provisionally approved in Australia, marking an important step forward in the management of metabolic dysfunction-associated steatohepatitis (MASH). The Therapeutic Goods Administration (TGA) has approved semaglutide (sold as Wegovy) for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis (stages F2 to… Read more